Marion Couch named chair of IU Head and Neck Surgery

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

MARION COUCH was named the Richard T. Miyamoto Professor and chair of the Indiana University School of Medicine Department of Otolaryngology-Head and Neck Surgery. Couch will assume her duties June 1, pending approval by the trustees of Indiana University.

A head and neck surgical oncologist, she is professor and interim chair of the Department of Surgery at the University of Vermont College of Medicine and surgeon-in-chief of Fletcher Allen Health Care.

She joined the University of Vermont faculty in 2010 as division chief of otolaryngology-head and neck surgery and was appointed interim chair and physician leader of surgery in 2011. She also served as interim chief of ophthalmology and associate vice president of finance for the UVM Medical Group.

Couch will succeed Richard Miyamoto, chair and Arilla Spence DeVault Professor of Otolaryngology-Head and Neck Surgery and medical director of audiology and speech language pathology.

Miyamoto performed Indiana’s first cochlear implant in 1979. In 1995, he and his team at Riley Hospital for Children implanted a device in a 16-month-old boy, the youngest ever to receive a cochlear implant at that time.

YOU MAY BE INTERESTED IN

Shearwood McClelland III’s grandfather was a ditchdigger who dreamed that his six Black daughters would become doctors. McClelland’s mother did not disappoint—she became the first Black woman board-certified in maternal fetal medicine in the history of the United States.  Now, McClelland is the chief medical officer of Cancer Health Equity at the University of Oklahoma...

As oncology enters a new era of precision medicine, the Food and Drug Administration’s evolving biomarker strategy aims to ensure that life-saving therapies are tailored to individual patient needs, fostering safer and more effective treatments.  Historically, therapies were approved with broad indications based on overall efficacy, even when outcomes for biomarker-positive and -negative patients were...

In the evolving landscape of pediatric oncology, survivorship research has become an essential component of our mission to improve long-term patient outcomes. At City of Hope, we are focused on not only curing childhood cancers but also ensuring that survivors live the healthiest lives possible. A significant part of my research has been dedicated to mitigating the long-term toxicities of cancer therapy—particularly cardiovascular complications that can arise decades after treatment.

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login